One of the most significant clinical manifestations of massive transfusion syndrome is bleeding, usually from the surgical wound, injury or puncture spot; it is rarely generalized with bleeding into the skin or mucous membrane [1, 4, 7].
The results of screening tests in massive transfusion syndrome show thrombocytopenia, with the extension of the activated partial thromboplastin time (APTT) and prothrombin time (PT) and thrombin time normal values (TT).
In order to prevent the SEC, hemostasis test was repeated every 8 hours in the patients with massive transfusion syndrome.
Screening test results reported in many foreign [1, 15, 17, 21-26] and national medical publications [4, 16, 18] showed that massive transfusion syndrome, in addition to the reduced number of platelets, leads to the extension of the APTT and PT and normal TT values.
An attempt was made within this study during the five-year period to monitor and analyze chemotherapy with massive transfusion syndrome in a small group of patients.
One of the shortcomings of this study is that it followed a small group of patients with massive transfusion syndrome over a short period of time and at only one medical center in Belgrade, unlike foreign multidisciplinary studies which include several decades of research with a greater number of patients at several medical institutions.
For these reasons, further research should be undertaken over a longer period of time, which would involve several hospital centers in the Republic of Serbia and analyze chemotherapy outcome in a larger sample of patients with massive transfusion syndrome.